Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia
Padidela R et al. Calcif Tissue Int. 2021;108(5):622-633
ERN-BOND is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are Funded by the European Commission. For more information about the ERNs and the EU health strategy, please visit ec.europa.eu/health/ern
Funded by the European Union
ERN BOND Specific Grant Agreement no. 101157116
Coordinating Center
Istituto Ortopedico Rizzoli
via G.C.Pupilli, 1 – 40136 Bologna – Italy
“Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA. Neither the European Union nor the granting authority can be held responsible for them.”
Co-funded by the European Union
ERN BOND Specific Grant Agreement no. 101157116
Coordinating Center
Istituto Ortopedico Rizzoli
via G.C.Pupilli, 1 – 40136 Bologna – Italy
The contents of this website represents the views of the network and is its sole responsibility; and do not necessarily reflect the opinion of the European Union
